List view / Grid view
11 January 2016 | By Victoria White
Oral mucositis is a common and often debilitating complication of cancer treatment which affects 80% of patients with head and neck cancer receiving radiotherapy...
8 January 2016 | By Victoria White
ViiV Healthcare has formalised its collaboration with Janssen for the Phase III investigation and commercialisation of the injectable formulations of cabotegravir and rilpivirine...
8 January 2016 | By Victoria White
Median overall survival from the updated study results was 11.4 months in people with higher levels of PD-L1 expression, and 7.9 months in the overall study population...
8 January 2016 | By Victoria White
GlobalData states that the leading driver of this reasonably robust growth will be the anticipated launches of five biologics for the treatment of various forms of vasculitis...
7 January 2016 | By RADWAG
The X2 series embodies synergy between conventional solutions characteristic for high quality balances, and technology intended mainly for professional standards...
7 January 2016 | By Nicholas Jackson
Faron has announced that its Japanese licensing partner Maruishi has obtained positive results from the Phase II Japanese study for Traumakine conducted by Maruishi in Japan...
7 January 2016 | By Nicholas Jackson
DS Biopharma has announced positive top-line Phase IIa trial results for DS107 as an oral treatment for moderate to severe atopic dermatitis...
7 January 2016 | By Nicholas Jackson
PROGNOSIS study published in the New England Journal of Medicine reveals that an innovative Roche blood test can be used as a predictive tool for preeclampsia...
6 January 2016 | By Victoria White
The Phase 1 study, initiated by Washington University, will evaluate VS-6063 in combination with pembrolizumab and gemcitabine in patients with pancreatic cancer...
6 January 2016 | By Victoria White
Pharming has completed patient enrolment in the Phase 2 clinical study of Ruconest (recombinant C1 esterase Inhibitor, 50 IU/kg) for prophylaxis in patients with hereditary angioedema (HAE).
6 January 2016 | By Victoria White
The objective of the Phase 1 study is to evaluate the safety and tolerability of ARGX-113 and to identify a potential dose for future Phase 2 studies...
6 January 2016 | By Victoria White
The studies demonstrated that TAF was non-inferior to Gilead’s Viread (tenofovir disoproxil fumarate, TDF) based on the percentage of patients with HBV DNA levels below 29 IU/mL at 48 weeks of therapy...
6 January 2016 | By Victoria White
Newly presented data from the largest real world study to date demonstrate effectiveness of biosimilar infliximab in patients with inflammatory bowel diseases who have been switched from reference infliximab...
5 January 2016 | By Victoria White
GBI Research states that this strong growth will be primarily due to substantial increases in the prevalence of breast cancer, with rates of the disease expected to rise over the forecast period due to an aging population, changing lifestyles and higher survival rates...
5 January 2016 | By Victoria White
IONIS-HTTRx is a Gen. 2.0+ antisense drug in development for the treatment of Huntington's disease...
